Estrella Immunopharma, Inc.
Public company- Headquarters
- EMERYVILLE, California
- Industry
- Biotechnology
- Ticker
- ESLA
- CIK
- 0001844417
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CEOCynthia Pussinen | Oct 29, 2026 | Appointed |
| Chief Scientific OfficerCheng Liu, Ph.D. | Oct 29, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Cardiff Oncology, Inc.
CMO appointed: Leila Alland
- Vaxart, Inc.
member of the Board appointed: Raquel C. Bono, M.D., M.B.A., FACS
- Executive appointment
CEO appointed: Cynthia Pussinen
Cynthia Pussinen was named Chief Executive Officer of Estrella Immunopharma, Inc., effective October 25, 2026. Cynthia Pussinen succeeds Cheng Liu, Ph.D.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 29, 2026Role: Chief Executive Officer
- Executive appointment
Chief Scientific Officer appointed: Cheng Liu, Ph.D.
Cheng Liu, Ph.D. was named Chief Scientific Officer of Estrella Immunopharma, Inc., effective October 25, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 29, 2026Role: Chief Scientific Officer
Last verified Nov 8, 2026